The absence of any standards and regulations is becoming increasingly problematic. At least 70 per cent of clinical trials are now being done in the community, outside of health-care institutions and their in-house REBs.
In response to the movement of trials into the community where they aren’t covered by institutional REBs, it’s reasonable to assume that the number of for-profit REBs has grown, although there are no definite estimates of their number. Drug companies pay these for-profit REBs a fee to review their trials.
streetfestival
lemmy.ca
streetfestival@lemmy.ca